Sareum Holdings (SAR)

 

SAR Share PerformanceMore

52 week high1.7250 28/09/16
52 week low0.5574 26/07/16
52 week change 0.0600 (7.36%)
4 week volume127,980,756 30/05/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Sareum to Present at the ICCS 2017

RNS Number: 3717I Sareum Holdings PLC 19 June 2017 (AIM: SAR) Sareum Holdings PLC ("Sareum" or the "Company") Sareum to Present at the International Cancer Cluster Showcase 2017 Dr Tim Mitchell, CEO of Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development business, will deliver a presentation at the 6th annual Internatio...

Sareum updates on Chk1 inhibitor trials

Sareum Holdings has confirmed that it has noted the announcement made today by Sierra Oncology, Inc. reporting on the...

Chk1 Clinical Trials Update

RNS Number: 1628H Sareum Holdings PLC 05 June 2017 (AIM: SAR) 5 June 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Chk1 Clinical Trials Update Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an...

Sareum Holdings notes Sierra Oncology patents

Sareum Holdings notes an announcement made by Sierra Oncology Inc yesterday that selection patents that explicitly prot...

Sierra Oncology Granted US and EU Patents

RNS Number: 6039G Sareum Holdings PLC 31 May 2017 (AIM: SAR) 31 May 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737 Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an announcement made by Sierra Oncology, Inc. ...

Sierra Oncology to Present at ASCO Annual Meeting

Sareum to Present at BioTrinity 2017

Director Deals - Sareum Holdings PLC (SAR)

Dr Stephen Parker, Chairman, bought 1,136,221 shares in the company on the 8th March 2017 at a price of 0.95p. The Direct...

Fundamental DataMore

EPS-0.04
Dividend yield0 %

Equity Research (SAR)

Sareum Holdings plc
06/06/2017
The specialist cancer drug discovery and development business yesterday flagged the progress announced by its licensing partner, Sierra Oncology’s (NASDAQ: SRRA) on the two ongoing Phase 1 trials...
Sareum Holdings plc
20/02/2017
The specialist cancer drug discovery and development business has reported HY December 2016 results registering a maiden net profit of £573k driven by the licensing deal agreed in September 2016 with...
Sareum Holdings plc
13/01/2017
The specialist cancer drug discovery and development business this week announced the attainment of a US$2m success milestone payment as part of the Chk1 licence agreement between its co-investment...

Latest discussion posts More

  • Dropping back

    This will not daily climb post latest rns
    5-Jun-2017
    clockwurktangerine
  • 2017

    No more spikes. No more deals...
    9-May-2017
    clockwurktangerine
  • Expectation

    Moved sp 0.2 to about 0.8 US deal and payments up to 1.2 but it has not held.... Deal on spikes...
    31-Mar-2017
    clockwurktangerine

Users' HoldingsMore

Users who hold Sareum Holdings also hold..
RANGE RES.17%
LLOYDS GRP.16%
ROCKHOPPER13%
SOLO OIL13%
SIRIUS MINERALS12%

Codes & Symbols

ISINGB00B02RFS12
SymbolsSAR, LSE:SAR, SAR.L, SAR:LN, LON:SAR, XLON:SAR